So far, the strongest studies have been observational
Dose comparison at 2.5 mg/mL At 2.5 mg/mL, 10 units is your starting dose
Semaglutide for managing overweight and obesity (TA875): Chapter 1 Recommendations
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 19 Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations Authors Ylmaz N , Bastemir M Received 27 November 2025 Accepted for publication 13 January 2026 Published 30 January 2026 Volume 2026:19 584175 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Dr Halis Akturk Nimet Ylmaz, 1 Mehmet Bastemir 2 1 Department of Gastroenterology, SANKO University Faculty of Medicine, Gaziantep, Turkey
Different pens presentation are available and are sold under brand names Ozempic and Wegovy, and have been approved to have a high impact on weight loss for overweight and obese people
Your provider can help manage symptoms and monitor your response